Cost of Oncology Drugs in the Middle-Eastern Country of Lebanon: An Update (2014-2016)
This study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and 2016 and to assess the impact of the introduction in mid-2015 of new immunotherapy drugs for the treatment of lung cancer on the overall and specifi...
Saved in:
Published in | Journal of global oncology Vol. 4; no. 4; pp. 1 - 7 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society of Clinical Oncology
01.09.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | This study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and 2016 and to assess the impact of the introduction in mid-2015 of new immunotherapy drugs for the treatment of lung cancer on the overall and specific costs of that treatment.
A secondary analysis of data from the MOPH Cancer Drug Scientific Committee data base was conducted using a total of 18,133 cancer files between 2014 and 2016.
Over the 3-year period, about $140 million (USD) was spent on cancer drugs by the MOPH free cancer drug dispensing program. The expenditures increased by 27% after immunotherapy was phased in. The average cost of drugs per patient per year measured across all cancer types increased from $7,000 in 2014 to $8,400 in 2016. Trastuzumab, approved for treating human epidermal growth factor receptor 2-positive breast cancer ranked first in total expenditures for 2014-2015. By 2016, two new immunotherapy drugs had topped the list: pembrolizumab ranked first and nivolumab ranked third, representing 64% of the total cost of lung cancer treatment and approximately 19% of the total yearly budget; beneficiaries represented only 3% of all patients.
This update documents the increasing financial impact of newer cancer drugs on the procurement process in the middle-income country of Lebanon. The trend is aligned with the financial burden of cancer drugs worldwide, which calls for a collaborative global response to this crisis. |
---|---|
AbstractList | Purpose: This study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and 2016 and to assess the impact of the introduction in mid-2015 of new immunotherapy drugs for the treatment of lung cancer on the overall and specific costs of that treatment. Methods: A secondary analysis of data from the MOPH Cancer Drug Scientific Committee data base was conducted using a total of 18,133 cancer files between 2014 and 2016. Results: Over the 3-year period, about $140 million (USD) was spent on cancer drugs by the MOPH free cancer drug dispensing program. The expenditures increased by 27% after immunotherapy was phased in. The average cost of drugs per patient per year measured across all cancer types increased from $7,000 in 2014 to $8,400 in 2016. Trastuzumab, approved for treating human epidermal growth factor receptor 2–positive breast cancer ranked first in total expenditures for 2014-2015. By 2016, two new immunotherapy drugs had topped the list: pembrolizumab ranked first and nivolumab ranked third, representing 64% of the total cost of lung cancer treatment and approximately 19% of the total yearly budget; beneficiaries represented only 3% of all patients. Conclusion: This update documents the increasing financial impact of newer cancer drugs on the procurement process in the middle-income country of Lebanon. The trend is aligned with the financial burden of cancer drugs worldwide, which calls for a collaborative global response to this crisis. PURPOSEThis study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and 2016 and to assess the impact of the introduction in mid-2015 of new immunotherapy drugs for the treatment of lung cancer on the overall and specific costs of that treatment. METHODSA secondary analysis of data from the MOPH Cancer Drug Scientific Committee data base was conducted using a total of 18,133 cancer files between 2014 and 2016. RESULTSOver the 3-year period, about $140 million (USD) was spent on cancer drugs by the MOPH free cancer drug dispensing program. The expenditures increased by 27% after immunotherapy was phased in. The average cost of drugs per patient per year measured across all cancer types increased from $7,000 in 2014 to $8,400 in 2016. Trastuzumab, approved for treating human epidermal growth factor receptor 2-positive breast cancer ranked first in total expenditures for 2014-2015. By 2016, two new immunotherapy drugs had topped the list: pembrolizumab ranked first and nivolumab ranked third, representing 64% of the total cost of lung cancer treatment and approximately 19% of the total yearly budget; beneficiaries represented only 3% of all patients. CONCLUSIONThis update documents the increasing financial impact of newer cancer drugs on the procurement process in the middle-income country of Lebanon. The trend is aligned with the financial burden of cancer drugs worldwide, which calls for a collaborative global response to this crisis. Purpose This study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and 2016 and to assess the impact of the introduction in mid-2015 of new immunotherapy drugs for the treatment of lung cancer on the overall and specific costs of that treatment. Methods A secondary analysis of data from the MOPH Cancer Drug Scientific Committee data base was conducted using a total of 18,133 cancer files between 2014 and 2016. Results Over the 3-year period, about $140 million (USD) was spent on cancer drugs by the MOPH free cancer drug dispensing program. The expenditures increased by 27% after immunotherapy was phased in. The average cost of drugs per patient per year measured across all cancer types increased from $7,000 in 2014 to $8,400 in 2016. Trastuzumab, approved for treating human epidermal growth factor receptor 2–positive breast cancer ranked first in total expenditures for 2014-2015. By 2016, two new immunotherapy drugs had topped the list: pembrolizumab ranked first and nivolumab ranked third, representing 64% of the total cost of lung cancer treatment and approximately 19% of the total yearly budget; beneficiaries represented only 3% of all patients. Conclusion This update documents the increasing financial impact of newer cancer drugs on the procurement process in the middle-income country of Lebanon. The trend is aligned with the financial burden of cancer drugs worldwide, which calls for a collaborative global response to this crisis. This study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and 2016 and to assess the impact of the introduction in mid-2015 of new immunotherapy drugs for the treatment of lung cancer on the overall and specific costs of that treatment. A secondary analysis of data from the MOPH Cancer Drug Scientific Committee data base was conducted using a total of 18,133 cancer files between 2014 and 2016. Over the 3-year period, about $140 million (USD) was spent on cancer drugs by the MOPH free cancer drug dispensing program. The expenditures increased by 27% after immunotherapy was phased in. The average cost of drugs per patient per year measured across all cancer types increased from $7,000 in 2014 to $8,400 in 2016. Trastuzumab, approved for treating human epidermal growth factor receptor 2-positive breast cancer ranked first in total expenditures for 2014-2015. By 2016, two new immunotherapy drugs had topped the list: pembrolizumab ranked first and nivolumab ranked third, representing 64% of the total cost of lung cancer treatment and approximately 19% of the total yearly budget; beneficiaries represented only 3% of all patients. This update documents the increasing financial impact of newer cancer drugs on the procurement process in the middle-income country of Lebanon. The trend is aligned with the financial burden of cancer drugs worldwide, which calls for a collaborative global response to this crisis. |
Author | Gebran, Anthony Adib, Salim M Gebran, Selim Bou-Orm, Ibrahim R Ammar, Walid Elias, Fadia |
Author_xml | – sequence: 1 givenname: Fadia surname: Elias fullname: Elias, Fadia organization: Fadia Elias, Ibrahim R. Bou-Orm, and Walid Ammar, Ministry of Public Health, Lebanon; Fadia Elias and Walid Ammar, Lebanese University; Salim M. Adib, Selim Gebran, Anthony Gebran, and Walid Ammar, American University of Beirut, Beirut, Lebanon; and Ibrahim R. Bou-Orm, Queen Margaret University, Edinburgh, United Kingdom – sequence: 2 givenname: Ibrahim R surname: Bou-Orm fullname: Bou-Orm, Ibrahim R organization: Fadia Elias, Ibrahim R. Bou-Orm, and Walid Ammar, Ministry of Public Health, Lebanon; Fadia Elias and Walid Ammar, Lebanese University; Salim M. Adib, Selim Gebran, Anthony Gebran, and Walid Ammar, American University of Beirut, Beirut, Lebanon; and Ibrahim R. Bou-Orm, Queen Margaret University, Edinburgh, United Kingdom – sequence: 3 givenname: Salim M surname: Adib fullname: Adib, Salim M organization: Fadia Elias, Ibrahim R. Bou-Orm, and Walid Ammar, Ministry of Public Health, Lebanon; Fadia Elias and Walid Ammar, Lebanese University; Salim M. Adib, Selim Gebran, Anthony Gebran, and Walid Ammar, American University of Beirut, Beirut, Lebanon; and Ibrahim R. Bou-Orm, Queen Margaret University, Edinburgh, United Kingdom – sequence: 4 givenname: Selim surname: Gebran fullname: Gebran, Selim organization: Fadia Elias, Ibrahim R. Bou-Orm, and Walid Ammar, Ministry of Public Health, Lebanon; Fadia Elias and Walid Ammar, Lebanese University; Salim M. Adib, Selim Gebran, Anthony Gebran, and Walid Ammar, American University of Beirut, Beirut, Lebanon; and Ibrahim R. Bou-Orm, Queen Margaret University, Edinburgh, United Kingdom – sequence: 5 givenname: Anthony surname: Gebran fullname: Gebran, Anthony organization: Fadia Elias, Ibrahim R. Bou-Orm, and Walid Ammar, Ministry of Public Health, Lebanon; Fadia Elias and Walid Ammar, Lebanese University; Salim M. Adib, Selim Gebran, Anthony Gebran, and Walid Ammar, American University of Beirut, Beirut, Lebanon; and Ibrahim R. Bou-Orm, Queen Margaret University, Edinburgh, United Kingdom – sequence: 6 givenname: Walid surname: Ammar fullname: Ammar, Walid organization: Fadia Elias, Ibrahim R. Bou-Orm, and Walid Ammar, Ministry of Public Health, Lebanon; Fadia Elias and Walid Ammar, Lebanese University; Salim M. Adib, Selim Gebran, Anthony Gebran, and Walid Ammar, American University of Beirut, Beirut, Lebanon; and Ibrahim R. Bou-Orm, Queen Margaret University, Edinburgh, United Kingdom |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30241263$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkc9v2yAUx9HUae2y3naeOHZSnT1-GMwOk6q06zplymXdFWH8nLpyTAr2pPz3I01XtRwAwUef9-D7nhwNYUBCPjKYMw7w5ef1as70HIBp84accKGrwpSgjl7sj8lpSveQmVJxzvU7ciyAS8aVOCF_FiGNNLR0NfjQh_WOXsZpnWg30PEO6a-uaXosrlwaMQ50EaZhjLs9v8Ta5Wa-0ouB3m4bNyI948BkkSf1-QN527o-4enTOiO3369-L34Uy9X1zeJiWXhZwlgYrypfAmLd6qYSXHpnuKs856iq3L_AStfcl2UtOPMMpALmFUjUVWWwRTEjNwdvE9y93cZu4-LOBtfZx4MQ19bFsfM9WgNKyqxsPeyLq9oYLSWrfcXKErXMrm8H13aqN9h4zE91_Svp65uhu7Pr8NfmXxV784ycPQlieJgwjXbTJY997wYMU7Kc5SFLA5DR8wPqY0gpYvtchoHdJ2tzspZp-5hsxj-9bO0Z_p-j-Ach05uw |
CitedBy_id | crossref_primary_10_4329_wjr_v12_i7_130 |
Cites_doi | 10.1200/JCO.2016.34.15_suppl.LBA6500 10.1002/1097-0142(196609)19:9<1293::AID-CNCR2820190917>3.0.CO;2-L 10.1001/jamaoncol.2016.0931 10.1001/jamaoncol.2015.0373 10.1200/JGO.2016.008607 10.1371/journal.pmed.1000344 10.1038/nrclinonc.2017.31 10.1016/S1470-2045(17)30235-8 |
ContentType | Journal Article |
Copyright | 2018 by American Society of Clinical
Oncology 2018 American Society of Clinical Oncology |
Copyright_xml | – notice: 2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1200/JGO.17.00179 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2378-9506 |
EndPage | 7 |
ExternalDocumentID | oai_doaj_org_article_90644783fc0c4506b997441bc8155e74 10_1200_JGO_17_00179 30241263 |
Genre | Journal Article |
GroupedDBID | 5VS AAAAV AAHPQ AAIQE AASCR ABASU ABDBF ABDIG ABVCZ ACILI ACXJB ADBBV ADGGA ADHPY ADPDF AFDTB AHQNM AHVBC AINUH AJNWD AJZMW ALMA_UNASSIGNED_HOLDINGS AMJPA AMKUR AMNEI AOHHW AOIJS BCNDV DIWNM EEVPB FBNNL FCALG FRP GNXGY GQDEL GROUPED_DOAJ H13 HLJTE HYE IKREB M~E NPM OK1 OPUJH OVD OVDNE PGMZT RHI RPM RUC TEORI TSPGW AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c450t-9c68c50eebf7d8324ca92a8c22e683783e87b2c55b321c104601c604e7889efe3 |
IEDL.DBID | RPM |
ISSN | 2378-9506 |
IngestDate | Fri Oct 04 13:06:56 EDT 2024 Tue Sep 17 21:16:23 EDT 2024 Fri Aug 16 21:58:44 EDT 2024 Fri Aug 23 01:52:23 EDT 2024 Wed Oct 16 00:49:30 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Issue | 4 |
Language | English |
License | Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c450t-9c68c50eebf7d8324ca92a8c22e683783e87b2c55b321c104601c604e7889efe3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223478/ |
PMID | 30241263 |
PQID | 2111145900 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_90644783fc0c4506b997441bc8155e74 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6223478 proquest_miscellaneous_2111145900 crossref_primary_10_1200_JGO_17_00179 pubmed_primary_30241263 |
PublicationCentury | 2000 |
PublicationDate | 2018-09-00 |
PublicationDateYYYYMMDD | 2018-09-01 |
PublicationDate_xml | – month: 09 year: 2018 text: 2018-09-00 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of global oncology |
PublicationTitleAlternate | J Glob Oncol |
PublicationYear | 2018 |
Publisher | American Society of Clinical Oncology |
Publisher_xml | – name: American Society of Clinical Oncology |
References | B10 B11 B12 B14 B15 B16 B17 Ammar W (B3) 2003 Ledford H (B6) 2013; 497 B1 American Society of Clinical Oncology (B13) IMS Institute for Healthcare Informatics (B5) Elias F (B4) 2016; 17 |
References_xml | – ident: B14 doi: 10.1200/JCO.2016.34.15_suppl.LBA6500 – ident: B13 publication-title: J Oncol Pract contributor: fullname: American Society of Clinical Oncology – volume-title: Global Oncology Trend Report: A Review of 2015 and Outlook to 2020 ident: B5 contributor: fullname: IMS Institute for Healthcare Informatics – volume-title: Health System and Reform in Lebanon year: 2003 ident: B3 contributor: fullname: Ammar W – ident: B1 doi: 10.1002/1097-0142(196609)19:9<1293::AID-CNCR2820190917>3.0.CO;2-L – ident: B11 doi: 10.1001/jamaoncol.2016.0931 – volume: 17 start-page: 3173 year: 2016 ident: B4 publication-title: Asian Pac J Cancer Prev contributor: fullname: Elias F – ident: B10 doi: 10.1001/jamaoncol.2015.0373 – ident: B17 doi: 10.1200/JGO.2016.008607 – ident: B12 doi: 10.1371/journal.pmed.1000344 – volume: 497 start-page: 544 year: 2013 ident: B6 publication-title: Nature contributor: fullname: Ledford H – ident: B15 doi: 10.1038/nrclinonc.2017.31 – ident: B16 doi: 10.1016/S1470-2045(17)30235-8 |
SSID | ssj0001562227 |
Score | 1.7719488 |
Snippet | This study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and 2016... Purpose This study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and... PURPOSEThis study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and... Purpose: This study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 1 |
SubjectTerms | Original Report |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT8MwDI4QB8QF8aa8FCSQ4FBo0jRJufHcNDF2YYhblWQpcOnQ1h3499hthzaExIVrGzWWP7e2a_sLIcdioJS0kKl6O0hDIZQNU6t4aF2ca29zk1dcet1H2e6LzkvyMnPUF_aE1fTAteIuUvCZQuk4d5ETSSRtChGwYNZp8IRe1UygLJlJppr5YBzybDrdwRIuOq3eOUO6QoZdWzM-qKLq_y2-_NkmOeN37lfJShMw0qta0DWy4It1stRtSuIb5PlmOC7pMKe9oiKg_qS3o8nrmL4XFGI72q1-QIR3piJEoDiCXo4-cf2DtwZy_0t6VdD-Byb-9BT8tACLZvJsk_Tv755u2mFzWEKIainD1EntksiDftUAXlPhTMqNdpx7iaTxsdfKcpckNubMYWU3Yk5GwkMOnPrcx1tkETb1O4QaLaz2uYFgzgrmuLHIwa7heYn2TEYBOZmqL_uoOTEyzCU4FsZavYxhSRvUHJBr1O33GmSyri4AvlmDb_YXvgE5miKTgeVjOcMUfjgZZxy_9gJPPQ3Ido3U91YxhB6Myzggag7DOVnm7xTvbxW7NhhODALt_ofwe2QZMNN1T9o-WSxHE38AQUxpDyt7_QLxzeo2 priority: 102 providerName: Directory of Open Access Journals |
Title | Cost of Oncology Drugs in the Middle-Eastern Country of Lebanon: An Update (2014-2016) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30241263 https://search.proquest.com/docview/2111145900 https://pubmed.ncbi.nlm.nih.gov/PMC6223478 https://doaj.org/article/90644783fc0c4506b997441bc8155e74 |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCbaHopehq17eY9CAzZgOzixHpbk3dr0hWJZdliG3gxJkbsAqx0kzqH_fpRiF83Q0662bMn8aJM0yU8AH8VMKWkxUvV2VqRCKJsWVrHUOl5pbytTRS698Xd5ORVX1_n1DuR9L0ws2nd2Pqj_3A7q-e9YW7m4dcO-Tmz4YzySaNOE0sNd2FWcPwjRu9bg0N_ZFbmjEgyvLiYDGpgKUfkOYJ-jWaJM8i1LFAn7H_My_y2WfGB9zp_Ck85tJMeb5T2DHV8fwv64S4w_h1-jZtWSpiKTOtJQ35HT5fpmReY1QQ-PjONviPTMRFoEEhrR2-VdGP_NW1M39VdyXJPpIoT_5DNaa4F6TeWXFzA9P_s5uky7LRNSJ_KsTQsntcszj1JWM3xZhTMFM9ox5mWgjudeK8tcnlvOqAv53Yw6mQmPkXDhK89fwh5O6l8DMVpY7SuDLp0V1DFjAxO7xvvl2lOZJfCpF1-52DBjlCGiYCE9djEpaUhso8QTOAmyvR8T-KzjgWZ5U3aolgV6Rogor1wWHkTaAuMcQa3T6O94JRL40CNTov6HpIapfbNelSx880XY-zSBVxuk7qfqkU5AbWG4tZbtM6hykWO7U7E3_33lWzhAoPSmHO0d7LXLtX-P_ktrj2LcfxS19i-wfe1D |
link.rule.ids | 230,315,733,786,790,870,891,2115,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa6Duh62fvhPTVgA7aDHUuWZXm3LmubdXGzQ1P0ZliK3AVb7SBxDt2vHyXbRVPssl0t2XqQNEmR_ATwjs-SRCj0VI2apT7nifJTlTBf6aiURpVF6bD0smMxmvKjs_hsC-K-FsYl7Ws1D6pfF0E1_-FyKxcXetDniQ2-Z0OBOo0ncnALbqO8sviak94VB9sKzy7NHdlgcHQ4CajFKkT224WdCBUTZSLa0EUOsv9vdubNdMlr-ufgHpz2M2_TTn4G60YF-vcNUMd_Xtp9uNtZpGSvbX4AW6Z6CDtZF3N_BKfDetWQuiSTyiFcX5Ivy_X5iswrgsYjydwJh79fOMQFYmvcm-Wl7T82qqjq6hPZq8h0YU8WyAc0BDiKDBUfH8P0YP9kOPK72xh8zeOw8VMtpI5DgwRMZvgf4LpIWSE1Y0ZYVPrIyEQxHccqYlTb0HFItQi5QSc7NaWJnsA2DmqeASkkV9KUBVqLilPNCmVB3iV-L5aGitCD9z1d8kULupFbZ4XZyNvhJKc2Zo6k9OCzJdpVHwuV7R7Uy_O829U8RaMLdzQqdWgXIlSKLhSnSks0pUzCPXjbkzxH0bLxkqIy9XqVM6tOuL1W1YOnLQtcDdWzkAfJBnNszGWzBUnu4Ls7Ej__7zffwJ3RSTbOx1-Pv72AXSSabLPeXsJ2s1ybV2gmNeq1E4o_FkIOUw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa2Dgh62fvhPTVgA7aDX7Isybt1adOua5oelqHoxbAUuQvaOkHiHLpfP0q2i6TYqVdbtiyRND-K1CeAT2wiBFcYqRo1yXzGhPIzJaivdFJKo8qidFx6w2N-MGaHp-np2lFfrmhfq2lQXV4F1fSPq62cX-mwqxMLT4Z9jj6NCRnOJ2V4Hx6gzVKxFqi3G4TtLs-21B1VITzcHwWx5StEFdyGXoLOKaY82fBHjrb_f1jzdsnkmg8aPIKz7uub0pOLYFWrQP-9Rex4p-E9hoctMiU7TZMncM9UT6E3bHPvz-B3f7asyawko8oxXV-T3cXqfEmmFUEQSYZupcPfKxzzArF73evFtW1_ZFRRzapvZKci47ldYSBfEBAwNJ2Yf30O48Her_6B357K4GuWRrWfaS51GhkUpJjg_4DpIqOF1JQabtnpEyOFojpNVUJjbVPIUax5xAwG25kpTfICtrBT8wpIIZmSpiwQNSoWa1ooS_Yu8X2pNDGPPPjcySafN-QbuQ1aqM3A7Y_y2ObOUZwefLeCu2ljKbPdhdniPG9nNs8QfOGsJqWO7EC4yjCUYrHSEiGVEcyDj53YczQxmzcpKjNbLXNq3Qqzx6t68LJRg5uuOjXyQGwoyMa3bN5BsTsa71bMr-_85AfonewO8qMfxz_fwDbKTDbFb29hq16szDtES7V67-ziH7g4ENM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cost+of+Oncology+Drugs+in+the+Middle-Eastern+Country+of+Lebanon%3A+An+Update+%282014-2016%29&rft.jtitle=Journal+of+global+oncology&rft.au=Elias%2C+Fadia&rft.au=Bou-Orm%2C+Ibrahim+R&rft.au=Adib%2C+Salim+M&rft.au=Gebran%2C+Selim&rft.date=2018-09-01&rft.eissn=2378-9506&rft.volume=4&rft.spage=1&rft.epage=7&rft_id=info:doi/10.1200%2FJGO.17.00179&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2378-9506&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2378-9506&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2378-9506&client=summon |